Med. praxi 2013; 10(8-9): 273-276

Combined hypolipidemic treatment in practice

doc.MUDr.Věra Adámková, CSc.
Institut klinické a experimentální medicíny, Kardiocentrum, Pracoviště preventivní kardiologie, Praha

The disorders of the lipid metabolism belong to the important modifiable factors of the manifestation of the atherosclerotis processes.

Dyslipidemia is characterized by the changing of the values of total cholesterol, triglycerides and high density cholesterol (HDL). Etiopathogenesis

of the dyslipidemia is very intensively studied, but clear explanation has not been done, yet. It is clear that the emergence

of dyslipidemia affect how genetic factors and lifestyle. Treatment is pharmacological and non-pharmacological, especially eating habits,

smoking, obesity (overweight) and physical activity. Where, non-pharmacological measures do not sufficiently effective, lauching

pharmacological treatment.

Keywords: dyslipidemia, hypolipidemic treatment, myopathy

Published: September 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adámková V. Combined hypolipidemic treatment in practice. Med. praxi. 2013;10(8-9):273-276.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vaverková H, Soška V, Rosolová H, Češka R, Cífková R, Freiberger T, Piťha J, Poledne R, Štulc T, Urbanová Z, Vráblík M. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitřní lékařství 2007; 53(2): 181-197. Go to PubMed...
    2. ÚZIS ČR, Aktuální informace, 2012; 24: 1-31.
    3. Vrablík M, V Komentář k Evropským doporučeným postupům prevence kardiovaskulárních onemocnění. Interní Med. 2012; 14(12): 489-490.
    4. Češka R. Cholesterol a ateroskleróza, léčba dyslipidemií, Triton, 1. vydání 2012: 408.
    5. Wanders D, Plaisance EP, Judd RL. Chapter Thirteen - Lipid-Lowering Drugs and Circulating Adiponectin Vitamins & Hormones 2012; 90: 341-374. Go to original source... Go to PubMed...
    6. Zlatohlávek L. Jak optimalizovat hladinu HDL cholesterolu? Interní Med. 2012; 14(2): 83-84.
    7. Adámková V. Nejnovější trendy léčby závažné dyslipidemie v praxi Practicus 2007; 1(6): 28-32.
    8. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 295-207. Go to original source... Go to PubMed...
    9. Ošťádal P. Hypolipidemická léčba u akutního koronárního syndromu Interní Med 2012; 14(11): 406-411.
    10. Matikainen N, Juhani Kahri J, Taskinen MR. Reviewing statin therapy in diabetes - Towards the best practise Primary Care Diabetes 2010; 4(1): 9-15. Go to original source... Go to PubMed...
    11. Camerion GM, Pellegrino MA, Brocca L, Digennaro C, Camerino DC, Pierno S, Botinelli R.Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle Biochemical Pharmacology 2011; 81: 1054-1064. Go to original source... Go to PubMed...
    12. Proya SM, Benitta TA, James C. Vibrational spectroscopis investigation and normal coocrdinate analysis of the fibrate hypolipidemic agent 5-(2,5-dimethylphenoxy)-2,2-dimethyl pentanoic acid (Genfibrozil) J Molecular Structure 2011; 990: 253-262. Go to original source...
    13. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic efects of ezetimib: Do they really exist? European Journal of Pharmacology 2010; 633(1-3): 62-70. Go to original source... Go to PubMed...
    14. Han S, Levoci L, Fischer P, Wang SP, Gagen K, Chen Y, Xie D, Fisher T, Ehrhardt AG, Peier AM, Johns DG. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the ani.inflammatory properties of high density lipoprotein. Biochim Biophys Acta 2013; 1831(4): 825-833. Go to original source... Go to PubMed...
    15. Garg A, Maes A, Corr C, Jin B, Wadhwa T, Handa N, m Can Dyck K, de Lepeleire I, Shah J, Wagner JA, Krishna R. Effect of Diltiazem a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester transfer Protein Inhibitor, in Healthy Subjects. J.Clin. Pharmacology 2011; 51: 436-439. Go to original source... Go to PubMed...
    16. Cignarella A, Bellosta S, Corsini A, Bolego Ch. Hypolipidemic therapy for the metabolic syndrome. Pharmacological Research 2006; 53: 492-500. Go to original source... Go to PubMed...
    17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. Diagnosis and management of the metabolic syndorme - an American Heart Association/Natinal Heart, Lung, and Blood Institute scientific statement, Circulation 2005; 112: 2735-2752.
    18. Weidong X, Yunan Z, Lijun D. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J. Ethnopharmacology 2012; 140: 345-367. Go to original source...
    19. Heeba GH, Abd-Elghany MI. Effect of combined administration of ginger (Zingiber officinale Roscoe) and atorvastatin on the liver of rats. Phytomedicine 2010; 17(14): 1076-1081. Go to original source... Go to PubMed...
    20. Sala-Vila A, Cofan M, Mateo-Gallego R, Cenarro A, Civeira F, Ortega E, Ros E. Inverse association between serum phospholipid oleic acid and insulin resistance in subjects with primary dyslipidaemia. Clinical Nutrition 2011; 30: 590-592. Go to original source... Go to PubMed...
    21. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidaemia? Pharmacotherapy to reduce cardiovascular risk.Pharmacology & Therapeutics 2010; 126(3): 314-345. Go to original source... Go to PubMed...
    22. Han SH, Oh P Ch, Lim S, Eckel RH, Koh KK. Comparative cardiometalobic effects of fibrates and omega 3 fatty acids. International Journal of Cardiology, In Press, Corrected Proof, Available online 27 February 2013.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.